Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Rhea-AI Summary
Foghorn Therapeutics (Nasdaq: FHTX) closed a $50 million registered direct financing on Jan 13, 2026, selling common stock and warrants.
The company sold 2,030,314 common shares at $6.71 per share (a 30% premium to the Jan 9, 2026 Nasdaq price), issued pre-funded warrants for up to 5,421,250 shares at $6.7099, and issued series warrants to buy 3,725,782 shares at $13.42 and another 3,725,782 shares at $20.13. Gross proceeds were approximately $50 million (excluding any proceeds from potential warrant exercises). The financing was sold directly by Foghorn without an underwriter and included participation by BVF Partners, Deerfield Management, Flagship Pioneering and a leading biotech mutual fund.
Positive
- Gross proceeds of approximately $50 million
- Issue price of $6.71 represented a 30% premium to Jan 9, 2026 Nasdaq price
- Sale included 2,030,314 common shares at $6.71
- Pre-funded warrants for up to 5,421,250 shares at $6.7099
Negative
- Series warrants could dilute up to 7,451,564 shares if exercised at higher strike prices
- Reported gross proceeds exclude any future proceeds from warrant exercises
- Offering increases outstanding convertible instruments with strikes at $13.42 and $20.13
News Market Reaction – FHTX
In the Jan 14 session, FHTX declined 5.54%, reflecting a notable negative market reaction. Argus tracked a peak move of +13.9% during that session. Argus tracked a trough of -3.4% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Conference participation | Neutral | +3.5% | Management participation in Evercore healthcare investor conference and webcast access. |
| Nov 05 | Earnings/corporate update | Positive | +13.3% | Q3 2025 financial update highlighting strong balance sheet and clinical progress. |
| Nov 03 | Investor conferences | Neutral | -4.5% | Announcement of participation in three November investor conferences with CEO presentations. |
| Oct 30 | Pipeline update | Positive | +1.9% | Preclinical progress update across selective ARID1B, CBP, and EP300 degrader programs. |
| Oct 16 | Pipeline progress | Positive | -2.5% | Announced significant ARID1B degrader progress and upcoming presentations and investor event. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company updates, especially financial and pipeline communications, have more often seen positive price alignment, with only one notable divergence on seemingly positive pipeline news.
Over the last few months, Foghorn has focused on investor engagement and pipeline communication. An October 30, 2025 update on ARID1B, CBP, and EP300 degraders and subsequent October summit-related news underscored progress in targeted degrader programs. Q3 2025 financials on Nov 5 highlighted cash strength and clinical advancement, followed by multiple November investor conferences and the Evercore Healthcare Conference appearance. Against this backdrop, today’s $50 million premium-priced financing follows a pattern of using capital and visibility to support a growing clinical pipeline.
Key Terms
registered direct financing financial
pre-funded warrants financial
series warrants financial
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its
The financing included existing shareholders BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund. No underwriter or placement agent participated in the offering.
The securities issued in the January Registered Direct Financing described above were offered by Foghorn pursuant to a shelf registration statement on Form S-3 declared effective by the Securities and Exchange Commission (“SEC”) on January 31, 2025. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. A prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and will be available on the SEC's website at www.sec.gov.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary, scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
